DOCSLIB.ORG

Table SI. List of Differentially Expressed Proteins Selected from Previous Proteomic Studies for Kyoto Encyclopedia for Genes and Genomes Pathway Analysis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Table SI. List of Differentially Expressed Proteins Selected from Previous Proteomic Studies for Kyoto Encyclopedia for Genes and Genomes Pathway Analysis Table SI. List of differentially expressed proteins selected from previous proteomic studies for Kyoto Encyclopedia for Genes and Genomes pathway analysis. A, LF (decreased expression) Gene GeneID Species Thrombospondin-4 450,172 Chimpanzee Nascent polypeptide-associated complex subunit α-2 454,797 Chimpanzee Microfibril-associated glycoprotein 4 744,007/454,500 Chimpanzee α-2 type I collagen 105,370,705 Human Asporin 54,829 Human Acetyl-CoA acetyltransferase 38/39 Human Mimecan 4,969 Human Fibulin-5 453,112 Chimpanzee α-1 type I collagen 107,984,355 Human Serum albumin 213 Human B, LF (increased expression) Gene GeneID Species Actin, aortic smooth muscle 59 Human α-1-antichymotrypsin 453,133 Chimpanzee Angiopoietin-related protein 1 74,0954 Chimpanzee Apolipoprotein A-I 335 Human Apolipoprotein B-100 338 Human Apolipoprotein C-III 345 Human ATP-binding cassette sub-family D member 3 100,172,102 Sumatran orangutan Carbonic anhydrase 1 759 Human Cartilage intermediate layer protein 1 8,483 Human Cathelicidin 820 Human Chondroadherin 1,101 Human Type VIII collagen 105,378,949 Human Type VI collagen 1,291 Human Complement C3 718 Human Dihydropyrimidinase 1,807 Human Fibrinogen 2,243/2,244/2,266 Human G protein-activated inward rectifier potassium channel 4 469,548/451,660 Chimpanzee Hemoglobin 3,048/3,039/3,049/3,047/3,044/3,042/ Human 3,046/3,050/3,040/3,045/3,043 Immunoglobulin Not applicable Human Inter-α-trypsin inhibitor 3,697/3,698/3,699/3,700 Human Lamin-A/C 100,757,316 Chinese hamster Lipopolysaccharide-binding protein 3,929 Human Aggrecan core protein 453,629 Chimpanzee α-1-antitrypsin 5,265 Human Annexin A1 301 Human Apolipoprotein A-IV 337 Human Apolipoprotein C-I 341 Human Apolipoprotein E 348 Human Bullous pemphigoid antigen 1 8,354,651 Schistosoma mansoni Carboxypeptidase B2 1,361 Human Cartilage oligomeric matrix protein 1,311 Human Cathepsin G 1,511 Human Clusterin 1,191 Human Type XV collagen 1,306 Human Complement C1q subcomponent subunit B 713 Human Complement C4-A 462,577 Chimpanzee Ferritin 2,495/2,512 Human Table SI. Continued. Gene GeneID Species Fibronectin 2,335 Human Glia-derived nexin 5,270 Human Hyaluronan and proteoglycan link protein 1 1,404 Human Insulin-like growth factor-binding protein 3,486/3,483 Human Lactadherin 4,240 Human Latent-transforming growth factor 459,143 Chimpanzee Lysozyme 4,069 Human C, AF soluble (decreased expression) Gene GeneID Species Collagen Type I Alpha 1 Chain 1,277 Human Collagen Type II Alpha 1 Chain 1,280 Human Collagen Type VI Alpha 3 Chain 1,293 Human Biglycan 633 Human Lysozyme 4,069 Human Collagen Type I Alpha 2 Chain 1,278 Human Collagen Type VI Alpha 2 Chain 1,292 Human Collagen Type XI Alpha 2 Chain 1,302 Human Angiogenin 283 Human D, AF soluble (increased expression) Gene GeneID Species Lumican 4,060 Human Thrombospondin 1 7,057 Human Superoxide Dismutase 3 6,649 Human Fibronectin 2,335 Human Clusterin 1,191 Human Milk Fat Globule-EGF Factor 8 Protein 4,240 Human E, AF insoluble (decreased expression) Gene GeneID Species Collagen Type II Alpha 1 Chain 1,280 Human Collagen Type XI Alpha 2 Chain 1,302 Human Collagen Type XI Alpha 1 Chain 1,301 Human F, AF insoluble (increased expression) Gene GeneID Species Collagen Type III Alpha 1 Chain 1,281 Human Decorin 1,634 Human Fibronectin 2,335 Human Clusterin 1,191 Human Aggrecan 176 Human Proline and Arginine Rich End Leucine Rich Repeat Protein 5,549 Human Cartilage Oligomeric Matrix Protein 1,311 Human G, NP soluble (decreased expression) Gene GeneID Species Collagen Type II Alpha 1 Chain 1,280 Human Hyaluronan And Proteoglycan Link Protein 1 1,404 Human Table SI. Continued. Gene GeneID Species Lysozyme 4,069 Human Serpin Family A Member 1 5,265 Human Chondroadherin 1,101 Human Angigenin 283 Human Fibroblast Growth Factor Binding Protein 2 83,888 Human Synaptotagmin Like 1 84,958 Human H, NP soluble (increased expression) Gene GeneID Species Biglycan 633 Human Lumican 4,060 Human Proline and Arginine Rich End Leucine Rich Repeat Protein 5,549 Human Cartilage Oligomeric Matrix Protein 1,311 Human Proteoglycan 4 10,216 Human Clusterin 1,191 Human Serpin Family E Member 2 5,270 Human Decorin 1,634 Human Osteoglycin 4,969 Human Fibronectin 2,335 Human ABI Family Member 3 Binding Protein 25,890 Human Phospholipase A2 Group IIA 5,320 Human Superoxide Dismutase 3 6,649 Human I, NP insoluble (decreased expression) Gene GeneID Species Collagen Type I Alpha 1 Chain 1,277 Human Collagen Type I Alpha 2 Chain 1,278 Human J, NP insoluble (increased expression) Gene GeneID Species Lumican 4,060 Human Fibronectin 2,335 Human Clusterin 1,191 Human Proline and Arginine Rich End Leucine Rich Repeat Protein 5,549 Human Cartilage Oligomeric Matrix Protein 1,311 Human Gene IDs from Kyoto Encyclopedia of Genes and Genomes Database. AF, annulus fibrosus; LF, ligamentum flavum; NP, nucleus pulposus. Table SII. Patient information for the KEGG pathway analysis of differentially expressed proteins based on previous proteomic studies. Patients information of proteomic analysis about LF. A, Lumbar spinal stenosis Sex Number Age Male 28 71±14 Female 26 70±20 B, Lumbar herniation (control) Sex Number Age Male 11 46±31 Female 8 55±20 Patients information of proteomic analysis about AF (Soluble and Insoluble) and NP (Soluble and Insoluble) Disorder Age Sex IVD level Scoliosis (control) 11 Female L3-L4 Scoliosis (control) 16 Female L2-L3 Scoliosis (control) 21 Female L2-L3 Scoliosis (control) 25 Female L1-L2 Scoliosis (control) 29 Male L2-L3 Trauma (control) 35 Male L1-L2 Scoliosis (control) 46 Female T12-L1 Disc degeneration 16 Male L4-L5 Disc degeneration 20 Male L4-L5 Disc degeneration 32 Female L4-L5 Disc degeneration 37 Female L4-L5 Disc degeneration 43 Female L4-L5 Disc degeneration 43 Female L4-L5 Disc degeneration 47 Male L4-L5 Disc degeneration 53 Female L4-L5 Table SIII. KEGG pathway enrichment analysis of differentially expressed pathways in LFH and in AF and NP degeneration. Input Background Term ID number number P-value Input Gene ID Complement and coagulation cascades hsa04610 8 79 5.66x10-13 5,265|718|1,191|713|1,361| 2,244|2,266|2,243 African trypanosomiasis hsa05143 4 35 2.99x10-7 335|3,040|3,043|3,039 Fat digestion and absorption hsa04975 4 41 5.38x10-7 335|39|337|338 Malaria hsa05144 4 49 1.05x10-6 3,040|3,043|3,039|1,311 ECM-receptor interaction hsa04512 4 82 7.34x10-6 1,291|2,335|1,311|1,101 Vitamin digestion and absorption hsa04977 3 24 7.94x10-6 335|337|338 Staphylococcus aureus infection hsa05150 3 57 8.98x10-5 713|2,266|718 Synthesis and degradation of ketone bodies hsa00072 2 10 1.3x10-4 39|38 Focal adhesion hsa04510 4 203 2.3x10-4 1,291|2,335|1,311|1,101 Protein digestion and absorption hsa04974 3 90 3.3x10-4 1,306|1,291|1,361 Terpenoid backbone biosynthesis hsa00900 2 22 5.5x10-4 39|38 Platelet activation hsa04611 3 122 7.8x10-4 2,244|2,266|2,243 Glyoxylate and dicarboxylate metabolism hsa00630 2 28 8.5x10-4 39|38 Butanoate metabolism hsa00650 2 28 8.5x10-4 39|38 Systemic lupus erythematosus hsa05322 3 136 1.06x10-3 713|1,511|718 Propanoate metabolism hsa00640 2 32 1.1x10-3 39|38 PI3K-Akt signaling pathway hsa04151 4 342 1.54x10-3 1,291|2,335|1,311|1,101 Tryptophan metabolism hsa00380 2 40 1.67x10-3 39|38 Pyruvate metabolism hsa00620 2 40 1.67x10-3 39|38 Fatty acid degradation hsa00071 2 44 2x10-3 39|38 Tuberculosis hsa05152 3 179 2.29x10-3 3,929|820|718 Valine, leucine and isoleucine degradation hsa00280 2 48 2.36x10-3 39|38 Fatty acid metabolism hsa01212 2 48 2.36x10-3 39|38 Mineral absorption hsa04978 2 52 2.75x10-3 2,495|2,512 Lysine degradation hsa00310 2 52 2.75x10-3 39|38 PPAR signaling pathway hsa03320 2 72 5.09x10-3 335|345 Pertussis hsa05133 2 75 5.5x10-3 713|718 Salivary secretion hsa04970 2 89 7.6x10-3 4,069|820 Amoebiasis hsa05146 2 100 9.46x10-3 1,511|2,335 Chagas disease (American trypanosomiasis) hsa05142 2 104 1.019x10-2 713|718 Carbon metabolism hsa01200 2 113 1.19x10-2 39|38 Phagosome hsa04145 2 155 2.14x10-2 1,311|718 Nitrogen metabolism hsa00910 1 17 2.546x10-2 759 Pantothenate and CoA biosynthesis hsa00770 1 18 2.686x10-2 1,807 Renin-angiotensin system hsa04614 1 23 3.381x10-2 1,511 beta-Alanine metabolism hsa00410 1 31 4.483x10-2 1,807 Prion diseases hsa05020 1 35 5.029x10-2 713 Drug metabolism-other enzymes hsa00983 1 46 6.515x10-2 1,807 Legionellosis hsa05134 1 55 7.714x10-2 718 p53 signaling pathway hsa04115 1 69 9.55 x10-2 3,486 Leishmaniasis hsa05140 1 74 1.0196x10-1 718 Bacterial invasion of epithelial cells hsa05100 1 78 1.071x10-1 2,335 Small cell lung cancer hsa05222 1 86 1.173x10-1 2,335 Salmonella infection hsa05132 1 86 1.173x10-1 3,929 NF-kappa B signaling pathway hsa04064 1 93 1.2613x10-1 3,929 Pancreatic secretion hsa04972 1 96 1.2988x10-1 1,361 AGE-RAGE signaling pathway in diabetic hsa04933 1 101 1.3611x10-1 2,335 complications Pyrimidine metabolism hsa00240 1 105 1.4106x10-1 1,807 Toll-like receptor signaling pathway hsa04620 1 106 1.4229x10-1 3,929 Vascular smooth muscle contraction hsa04270 1 120 1.5937x10-1 59 Lysosome hsa04142 1 123 1.6299x10-1 1,511 Alzheimer's disease hsa05010 1 168 2.1543x10-1 348 Transcriptional misregulation in cancer hsa05202 1 180 2.2886x10-1 3,486 Herpes simplex infection hsa05168 1 186 2.3549x10-1 718 Proteoglycans in cancer hsa05205 1 205 2.5612x10-1 2,335 Viral carcinogenesis hsa05203 1 205 2.5612x10-1 718 Table SIII.
Load more

Recommended publications
  • TACI:Fc Scavenging B Cell Activating Factor (BAFF) Alleviates Ovalbumin-Induced Bronchial Asthma in Mice
    EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 39, No. 3, 343-352, June 2007 TACI:Fc scavenging B cell activating factor (BAFF) alleviates ovalbumin-induced bronchial asthma in mice 1,2,3 2 Eun-Yi Moon and Sook-Kyung Ryu the percentage of non-lymphoid cells and no changes were detected in lymphoid cell population. 1 Department of Bioscience and Biotechnology Hypodiploid cell formation in BALF was decreased Sejong University by OVA-challenge but it was recovered by TACI:Fc Seoul 143-747, Korea treatment. Collectively, data suggest that asthmatic 2 Laboratory of Human Genomics symptom could be alleviated by scavenging BAFF Korea Research Institute of Bioscience and Biotechnology (KRIBB) and then BAFF could be a novel target for the Daejeon 305-806, Korea develpoment of anti-asthmatic agents. 3 Corresponding author: Tel, 82-2-3408-3768; Fax, 82-2-466-8768; E-mail, [email protected] Keywords: asthma; B-cell activating factor; ovalbu- and [email protected] min; transmembrane activator and CAML interactor protein Accepted 28 March 2007 Introduction Abbreviations: BAFF, B cell activating factor belonging to TNF- family; BALF, bronchoalveolar lavage fluid; OVA, ovalbumin; PAS, Mature B cell generation and maintenance are regu- periodic acid-Schiff; Prx, peroxiredoxin; TACI, transmembrane lated by B-cell activating factor (BAFF). BAFF is pro- activator and calcium modulator and cyclophilin ligand interactor duced by macrophages or dendritic cells upon stim- ulation with LPS or IFN- . BAFF belongs to the TNF family. Its biological role is mediated by the specific Abstract receptors, B-cell maturation antigen (BCMA), trans- membrane activator and calcium modulator and cy- Asthma was induced by the sensitization and chal- clophilin ligand interactor (TACI) and BAFF receptor, lenge with ovalbumin (OVA) in mice.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Dietary Protein Restriction Rapidly Reduces Transforming Growth Factor
    Proc. Natl. Acad. Sci. USA Vol. 88, pp. 9765-9769, November 1991 Medical Sciences Dietary protein restriction rapidly reduces transforming growth factor p1 expression in experimental glomerulonephritis (extraceliular matrix/transforming growth factor 8/glomerulonephritis) SEIYA OKUDA*, TAKAMICHI NAKAMURA*, TATSUO YAMAMOTO*, ERKKI RUOSLAHTIt, AND WAYNE A. BORDER*t *Division of Nephrology, University of Utah School of Medicine, Salt Lake City, UT 84132; and tCancer Research Center, La Jolla Cancer Research Foundation, La Jolla, CA 92037 Communicated by Eugene Roberts, August 19, 1991 (receivedfor review April 29, 1991) ABSTRACT Dietary protein restriction has been shown to TGF-/31 on both cell types is to regulate the synthesis of two slow the rate of loss of kidney function in humans with chondroitin/dermatan sulfate proteoglycans, biglycan and progressive glomerulosclerosis due to glomerulonephritis or decorin, both of which can bind TGF-P1 (23). In an experi- diabetes mellitus. A central feature of glomerulosclerosis is the mental model ofglomerulonephritis in the rat, we have found pathological accumulation of extracellular matrix within the a close association between elevated expression of the diseased glomeruli. Transforming growth factor j1 (TGF-.81) TGF-131 gene and the development of glomerulonephritis is known to have widespread regulatory effects on extracellular (10). Seven days after glomerular injury, at the time of matrix and has been implicated as a major cause of increased significant extracellular matrix accumulation, the glomeruli extracellular matrix synthesis and buildup of pathological showed a 5-fold increase in TGF-f31 mRNA and a nearly matrix within glomeruli in experimental glomerulonephritis. 50-fold increase in production ofbiglycan and decorin.
    [Show full text]
  • Aggrecan (A1960)
    Aggrecan from bovine articular cartilage Catalog Number A1960 Storage Temperature –20 °C Product Description References Aggrecan is the major structural proteoglycan found in 1. Hardingham, T.E., and Muir, H., Biochim. Biophys. the extracellular matrix of cartilage. It has a molecular Acta, 279, 401-405 (1972). mass >2,500 kDa. The core protein (210–250 kDa) has 2. Hedlund, H., et al., Association of the aggrecan 100–150 glycosaminoglycan (GAG) chains attached to keratan sulfate-rich region with collagen in bovine it. The majority of the GAG chains are chondroitin/ articular cartilage. J. Biol. Chem., 274, 5777-5781 dermatan sulfate with the remainder being keratan (1999). sulfate. This structural molecule produces a rigid, 3. Cao, L., and Yang, B.B., Chondrocyte apoptosis reversibly deformable gel that resists compression. It induced by aggrecan G1 domain as a result of combines with hyaluronic acid to form very large decreased cell adhesion. Exp. Cell Res., 246, 527- macromolecular complexes. Addition of small amounts 537 (1999). (0.1–2% w/w) of hyaluronic acid to a solution of 4. Bolton, M.C., et al., Age-related changes in the aggrecan (2 mg/ml) results in the formation of a synthesis of link protein and aggrecan in human complex with an increased hydrodynamic volume and articular cartilage: implications for aggregate in a significant increase (30–40%) in the relative stability. Biochem. J., 337, 77-82 (1999). viscosity of the solution. 5. Arner, E.C., et al., Generation and Characterization of Aggrecanase. A soluble, cartilage-derived Aggrecan is a critical component for cartilage structure aggrecan-degrading activity.
    [Show full text]
  • Supplementary Materials
    Supplementary Materials Figure S1. Bioinformatics evaluation of dystrophin isoform Dp427 and its central position in the molecular pathogenesis of X-linked muscular dystrophy. In order to generate a protein interaction map with known and predicted protein associations that include direct physical and indirect functional protein linkages, the bioinformatics STRING database [1,2] was used to analyse mass spectrometrically-identified proteins with a changed abundance in mdx-4cv skeletal muscles (Tables 1 and 2). S2 Figure S2. Focus of the bioinformatics evaluation of dystrophin isoform Dp427 and its central position in the molecular pathogenesis of X-linked muscular dystrophy. Shown is the middle part of the interaction map of altered muscle-associated proteins from mdx-4cv hind limb muscles, focusing on the central position of the dystrophin protein Dp427 (marked in yellow). In order to generate a protein interaction map with known and predicted protein associations that include direct physical and indirect functional protein linkages, the bioinformatics STRING database [1,2] was used to analyse mass spectrometrically-identified proteins with a changed abundance in mdx-4cv skeletal muscles (Tables 1 and 2). S3 Table S1. List of identified proteins that exhibit a significantly altered concentration in crude mdx-4cv hind limb muscle preparations as revealed by label-free LC-MS/MS analysis. This table contains the statistical q-values of the proteins listed in Tables 1 and 2. Accession Peptide Max Fold Highest Mean Description q Value Number
    [Show full text]
  • The Brain Chondroitin Sulfate Proteoglycan Brevican Associates with Astrocytes Ensheathing Cerebellar Glomeruli and Inhibits Neurite Outgrowth from Granule Neurons
    The Journal of Neuroscience, October 15, 1997, 17(20):7784–7795 The Brain Chondroitin Sulfate Proteoglycan Brevican Associates with Astrocytes Ensheathing Cerebellar Glomeruli and Inhibits Neurite Outgrowth from Granule Neurons Hidekazu Yamada, Barbara Fredette, Kenya Shitara, Kazuki Hagihara, Ryu Miura, Barbara Ranscht, William B. Stallcup, and Yu Yamaguchi The Burnham Institute, La Jolla, California 92037 Brevican is a nervous system-specific chondroitin sulfate surface of these cells. Binding assays with exogenously proteoglycan that belongs to the aggrecan family and is one added brevican revealed that primary astrocytes and several of the most abundant chondroitin sulfate proteoglycans in immortalized neural cell lines have cell surface binding sites adult brain. To gain insights into the role of brevican in brain for brevican core protein. These cell surface brevican binding development, we investigated its spatiotemporal expression, sites recognize the C-terminal portion of the core protein and cell surface binding, and effects on neurite outgrowth, using are independent of cell surface hyaluronan. These results rat cerebellar cortex as a model system. Immunoreactivity of indicate that brevican is synthesized by astrocytes and re- brevican occurs predominantly in the protoplasmic islet in tained on their surface by an interaction involving its core the internal granular layer after the third postnatal week. protein. Purified brevican inhibits neurite outgrowth from Immunoelectron microscopy revealed that brevican is local- cerebellar granule neurons in vitro, an activity that requires ized in close association with the surface of astrocytes that chondroitin sulfate chains. We suggest that brevican pre- form neuroglial sheaths of cerebellar glomeruli where incom- sented on the surface of neuroglial sheaths may be control- ing mossy fibers interact with dendrites and axons from ling the infiltration of axons and dendrites into maturing resident neurons.
    [Show full text]
  • T Cell Reactivity + Autoantibodies and CD4 Therapy Is Mediated By
    Suppression of Proteoglycan-Induced Arthritis by Anti-CD20 B Cell Depletion Therapy Is Mediated by Reduction in Autoantibodies and CD4 + T Cell Reactivity This information is current as of September 27, 2021. Keith Hamel, Paul Doodes, Yanxia Cao, Yumei Wang, Jeffrey Martinson, Robert Dunn, Marilyn R. Kehry, Balint Farkas and Alison Finnegan J Immunol 2008; 180:4994-5003; ; doi: 10.4049/jimmunol.180.7.4994 Downloaded from http://www.jimmunol.org/content/180/7/4994 References This article cites 48 articles, 20 of which you can access for free at: http://www.jimmunol.org/ http://www.jimmunol.org/content/180/7/4994.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 27, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2008 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Suppression of Proteoglycan-Induced Arthritis by Anti-CD20 B Cell Depletion Therapy Is Mediated by Reduction in Autoantibodies and CD4؉ T Cell Reactivity1 Keith Hamel,* Paul Doodes,* Yanxia Cao,† Yumei Wang,† Jeffrey Martinson,* Robert Dunn,§ Marilyn R.
    [Show full text]
  • Biglycan Expression and Its Function in Human Ligamentum Flavum
    www.nature.com/scientificreports OPEN Biglycan expression and its function in human ligamentum favum Hamidullah Salimi, Akinobu Suzuki*, Hasibullah Habibi, Kumi Orita, Yusuke Hori, Akito Yabu, Hidetomi Terai, Koji Tamai & Hiroaki Nakamura Hypertrophy of the ligamentum favum (LF) is a major cause of lumbar spinal stenosis (LSS), and the pathology involves disruption of elastic fbers, fbrosis with increased cellularity and collagens, and/or calcifcation. Previous studies have implicated the increased expression of the proteoglycan family in hypertrophied LF. Furthermore, the gene expression profle in a rabbit experimental model of LF hypertrophy revealed that biglycan (BGN) is upregulated in hypertrophied LF by mechanical stress. However, the expression and function of BGN in human LF has not been well elucidated. To investigate the involvement of BGN in the pathomechanism of human ligamentum hypertrophy, frst we confrmed increased expression of BGN by immunohistochemistry in the extracellular matrix of hypertrophied LF of LSS patients compared to LF without hypertrophy. Experiments using primary cell cultures revealed that BGN promoted cell proliferation. Furthermore, BGN induces changes in cell morphology and promotes myofbroblastic diferentiation and cell migration. These efects are observed for both cells from hypertrophied and non-hypertrophied LF. The present study revealed hyper-expression of BGN in hypertrophied LF and function of increased proteoglycan in LF cells. BGN may play a crucial role in the pathophysiology of LF hypertrophy through cell proliferation, myofbroblastic diferentiation, and cell migration. Lumbar spinal stenosis (LSS) is the most common spinal disorder among the elderly population. Hypertrophic changes in the ligamentum favum (LF) are one of the major factors of LSS.
    [Show full text]
  • Syndecan - Regulation and Function of Its Glycosaminoglycan Chains
    Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 884 Syndecan - Regulation and Function of its Glycosaminoglycan Chains ANNA S. ERIKSSON ACTA UNIVERSITATIS UPSALIENSIS ISSN 1651-6206 ISBN 978-91-554-8637-2 UPPSALA urn:nbn:se:uu:diva-197691 2013 Dissertation presented at Uppsala University to be publicly examined in A1:107a, BMC, Husargatan 3, Uppsala, Friday, May 17, 2013 at 13:15 for the degree of Doctor of Philosophy (Faculty of Medicine). The examination will be conducted in English. Abstract Eriksson, A. S. 2013. Syndecan - Regulation and Function of its Glycosaminoglycan Chains. Acta Universitatis Upsaliensis. Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 884. 54 pp. Uppsala. ISBN 978-91-554-8637-2. The cell surface is an active area where extracellular molecules meet their receptors and affect the cellular fate by inducing for example cell proliferation and adhesion. Syndecans and integrins are two transmembrane molecules that have been suggested to fine-tune these activities, possibly in cooperation. Syndecans are proteoglycans, i.e. proteins with specific types of carbohydrate chains attached. These chains are glycosaminoglycans and either heparan sulfate (HS) or chondroitin sulfate (CS). Syndecans are known to influence cell adhesion and signaling. Integrins in turn, are important adhesion molecules that connect the extracellular matrix with the cytoskeleton, and hence can regulate cell motility. In an attempt to study how the two types of glycosaminoglycans attached to syndecan-1 can interact with integrins, a cell based model system was used and functional motility assays were performed. The results showed that HS, but not CS, on the cell surface was capable of regulating integrin-mediated cell motility.
    [Show full text]
  • Biglycan Recruits Utrophin to the Sarcolemma and Counters Dystrophic Pathology in Mdx Mice
    Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice Alison R. Amentaa, Atilgan Yilmazb, Sasha Bogdanovichc, Beth A. McKechniea, Mehrdad Abedid, Tejvir S. Khuranac, and Justin R. Fallona,1 aDepartment of Neuroscience and bDepartment of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI 02912; cDepartment of Physiology and Pennsylvania Muscle Institute, University of Pennsylvania School of Medicine, Philadelphia, PA 19104; and dDivision of Hematology and Oncology, University of California–Davis Medical Center, Sacramento, CA 95817 Edited by Louis M. Kunkel, Children’s Hospital Boston, Boston, MA, and approved November 22, 2010 (received for review September 2, 2010) Duchenne muscular dystrophy (DMD) is caused by mutations in dys- associated utrophin in cultured myotubes. Importantly, rhBGN trophin and the subsequent disruption of the dystrophin-associated can be delivered systemically to dystrophin-deficient mdx mice, protein complex (DAPC). Utrophin is a dystrophin homolog ex- where it up-regulates utrophin and other DAPC components at pressed at high levels in developing muscle that is an attractive the sarcolemma, ameliorates muscle pathology, and improves target for DMD therapy. Here we show that the extracellular matrix function. Several lines of evidence indicate that biglycan acts by protein biglycan regulates utrophin expression in immature muscle recruiting utrophin to the plasma membrane. We propose rhBGN and that recombinant human biglycan (rhBGN) increases utrophin as a candidate therapeutic for DMD. expression in cultured myotubes. Systemically delivered rhBGN up- regulates utrophin at the sarcolemma and reduces muscle pathology Results in the mdx mouse model of DMD. RhBGN treatment also improves Endogenous Biglycan Regulates Utrophin Expression in Immature muscle function as judged by reduced susceptibility to eccentric Muscle.
    [Show full text]
  • Fibroblasts from the Human Skin Dermo-Hypodermal Junction Are
    cells Article Fibroblasts from the Human Skin Dermo-Hypodermal Junction are Distinct from Dermal Papillary and Reticular Fibroblasts and from Mesenchymal Stem Cells and Exhibit a Specific Molecular Profile Related to Extracellular Matrix Organization and Modeling Valérie Haydont 1,*, Véronique Neiveyans 1, Philippe Perez 1, Élodie Busson 2, 2 1, 3,4,5,6, , Jean-Jacques Lataillade , Daniel Asselineau y and Nicolas O. Fortunel y * 1 Advanced Research, L’Oréal Research and Innovation, 93600 Aulnay-sous-Bois, France; [email protected] (V.N.); [email protected] (P.P.); [email protected] (D.A.) 2 Department of Medical and Surgical Assistance to the Armed Forces, French Forces Biomedical Research Institute (IRBA), 91223 CEDEX Brétigny sur Orge, France; [email protected] (É.B.); [email protected] (J.-J.L.) 3 Laboratoire de Génomique et Radiobiologie de la Kératinopoïèse, Institut de Biologie François Jacob, CEA/DRF/IRCM, 91000 Evry, France 4 INSERM U967, 92260 Fontenay-aux-Roses, France 5 Université Paris-Diderot, 75013 Paris 7, France 6 Université Paris-Saclay, 78140 Paris 11, France * Correspondence: [email protected] (V.H.); [email protected] (N.O.F.); Tel.: +33-1-48-68-96-00 (V.H.); +33-1-60-87-34-92 or +33-1-60-87-34-98 (N.O.F.) These authors contributed equally to the work. y Received: 15 December 2019; Accepted: 24 January 2020; Published: 5 February 2020 Abstract: Human skin dermis contains fibroblast subpopulations in which characterization is crucial due to their roles in extracellular matrix (ECM) biology.
    [Show full text]
  • Decorin and Biglycan Expression and Distribution During
    DECORIN AND BIGLYCAN EXPRESSION AND DISTRIBUTION DURING PALATAL SHELF ADHESION A Thesis by ISRA M. IBRAHIM Submitted to the Office of Graduate and Professional Studies of Texas A&M University in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Chair of Committee, Kathy Svoboda Committee Members, Louis-Bruno Ruest Xiaofang Wang Head of Department, Paul Dechow May 2015 Major Subject: Oral Biology Copyright 2015 Isra M. Ibrahim ABSTRACT Understanding the molecular events in palate development is a prerequisite to more effective treatments of cleft palate. The secondary palate in humans and mice forms from shelves of mesenchyme covered with medial edge epithelium (MEE). These shelves adhere to form the midline epithelial seam (MES). MES cells then proceed through epithelial to mesenchymal transition (EMT) and/or apoptosis to yield a fused palate. Adhesion of opposing MEE is a crucial event whose alteration causes cleft palate. Previous studies showed that chondroitin sulphate proteoglycans (CSPG) on the apical surfaces of MEE was an important factor in palatal shelf adhesion. In this study we investigated decorin and biglycan, being expressed in numerous craniofacial tissues, as potential proteoglycans involved in palatal shelf adhesion. We used a laser capture microdissection (LCM) technique to collect MEE cells and real-time polymerase chain reaction, to determine mRNA levels of decorin and biglycan that correctly reflect changes in gene expression during various stages of palatal shelf fusion (Embryonic days 13.5, 14.0 and 14.5). Both decorin and biglycan were expressed on the apical surface as well as between the MEE cells. We found that biglycan protein and mRNA levels peaked as the palatal shelves adhered.
    [Show full text]